I would love for you to talk to us about what is it, why is it important, and why is it gonna matter for us as a society.

Those are big questions.

So, um, [chuckles] I will say, uh, maybe just to take a step back, um, you know, when we think about treating metastatic triple-negative breast cancer, I think it's really critical that we think about making sure we're making the right treatment decision for our patients as that very first therapy that they're getting.

And for a while now, we've had antibody drug conjugates available for metastatic triple-negative disease, and the first one being sacituzumab govitecan, which had been approved several years ago, but it was for patients who had pre-treated metastatic triple-negative breast cancer.

So, um, in essence, it got approved for patients who were getting their second or later line treatment and in fact showed that it kept cancer controlled almost three times as long as standard chemotherapy.

It doubled survival.

Um, so it was a huge impact for patients, um, compared to our standard treatments at the time.

If I'm a newly diagnosed metastatic patient, how do I know it's triple-negative? How do I know if it's PD-L1? How should I be thinking about what happens?